Trials / Completed
CompletedNCT02110394
Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia
Observational Program for Evaluation of Ribomustin Use in the First Line Therapy of Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 190 (actual)
- Sponsor
- Astellas Pharma Europe B.V. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the first line therapy of chronic lymphocytic leukemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | bendamustine | Routine practice |
| OTHER | rituximab | Routine practice |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2014-04-10
- Last updated
- 2016-07-06
Locations
34 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT02110394. Inclusion in this directory is not an endorsement.